• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 202

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2021 Aug 13;27(11).
doi: 10.3201/eid2711.211190. Online ahead of print.
Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021

Catherine A Hogan, Agatha N Jassem, Hind Sbihi, Yayuk Joffres, John R Tyson, Kyle Noftall, Marsha Taylor, Tracy Lee, Chris Fjell, Amanda Wilmer, John Galbraith, Marc G Romney, Bonnie Henry, Mel Krajden, Eleni Galanis, Natalie Prystajecky, Linda M N Hoang
Free article

Abstract

Several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs) emerged in late 2020; lineage B.1.1.7 initially dominated globally. However, lineages B.1.351 and P.1 represent potentially greater risk for transmission and immune escape. In British Columbia, Canada, B.1.1.7 and B.1.351 were first identified in December 2020 and P.1 in February 2021. We combined quantitative PCR and whole-genome sequencing to assess relative contribution of VoCs in nearly 67,000 infections during the first 16 weeks of 2021 in British Columbia. B.1.1.7 accounted for <10% of screened or sequenced specimens early on, increasing to >50% by week 8. P.1 accounted for <10% until week 10, increased rapidly to peak at week 12, and by week 13 codominated within 10% of rates of B.1.1.7. B.1.351 was a minority throughout. This rapid expansion of P.1 but suppression of B.1.351 expands our understanding of population-level VoC patterns and might provide clues to fitness determinants for emerging VoCs.

Keywords: British Columbia; COVID-19; Canada; January–April 2021. Emerg Infect Dis. 2021 Nov [date cited]. https://doi.org/10.3201/eid2711.211190; Jassem AN; Joffres Y; Noftall K; SARS-CoV-2; Sbihi H; Suggested citation for this article: Hogan CA; Tyson JR; coronavirus disease; et al. Rapid increase in SARS-CoV-2 P.1 lineage leading to codominance with B.1.1.7 lineage; public health; respiratory infections; severe acute respiratory syndrome coronavirus 2; testing; variant of concern; viruses; zoonoses.
 
Back
Top Bottom